Help us improve Portfolio Grader.

Help us improve Portfolio Grader.

Blue Chip Growth

Stock Report: "SciClone Pharmaceuticals, Inc." (SCLN) Report Updated: Feb 08, 2016 | Print This Page

Get more stock ratings by Louis Navellier

"SciClone Pharmaceuticals, Inc." (SCLN)

Rating: Buy Volatility: Moderate
Total Grade: B Industry: Pharmaceuticals
Competitors: JNP, HSKA, NVO, AXN

Stock Analysis

Rating: Monthly View

February March April May June July August September October November December January

Rating: Weekly View

This Week: B down no change
Last Week: B same no change
Two Weeks Ago: B up no change
service keys

"SciClone Pharmaceuticals, Inc."© quotemedia

Company Profile

SciClone Pharmaceuticals, Inc. provides therapies for the treatment of oncology, infectious diseases, cardiovascular, urological, respiratory, and central nervous system disorders in the Peoples Republic of China and internationally. Its principal product is ZADAXIN, which is used for the treatment of hepatitis B and hepatitis C viruses, and certain cancers, as well as for use as a vaccine adjuvant, and as a chemotherapy adjuvant for cancer patients with weakened immune systems. ZADAXIN has approval in approximately 30 countries, which include China, the Pacific Rim, Latin America, eastern Europe, and the Middle East. The company markets and sells ZADAXIN through distribution arrangements, local importers, and distributors. It also offers Tramadol for use in the treatment of moderate to severe pain; and is developing SCV-07, which is in Phase IIb clinical trials for the treatment of oral mucositis and hepatitis C virus. In addition, the company markets partnered products in China, including Depakine, an anti-convulsant; Tritace, an ACE inhibitor for the treatment of hypertension; Stilnox, a hypnotic for the short-term treatment of insomnia; and Aggrastat, a cardiology product. It holds license, promotion, distribution, or marketing agreements for products, such as DC Bead, Loramyc, and ondansetron RapidFilm. SciClone Pharmaceuticals, Inc. was founded in 1989 and is headquartered in Foster City, California.

Recent News: "SciClone Pharmaceuticals, Inc."